Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

K Dredge, J B Marriott, C D Macdonald, H-W Man, R Chen, G W Muller, D Stirling, A G Dalgleish, K Dredge, J B Marriott, C D Macdonald, H-W Man, R Chen, G W Muller, D Stirling, A G Dalgleish

Abstract

The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation thalidomide analogues are distinct compounds with enhanced therapeutic potential. Although these compounds are beginning to enter trials for the treatment of cancer there is very little information regarding the anti-angiogenic activity of these clinically relevant compounds. Furthermore, it is not known how the various immunomodulatory activities of these compounds relate to anti-angiogenic activity. In this study we assessed the anti-angiogenic activity of compounds from both IMiD and SelCID classes of analogues using a novel in vitro multicellular human assay system and the established rat aorta assay. Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide. The anti-angiogenic potency of the analogues was not related to inhibition of endothelial cell proliferation, nor their TNF-alpha/PDE type 4 inhibitory properties. However, anti-migratory effects in vitro and inhibition of tumour growth in vivo was observed with the analogue IMiD-1 (clinically known as REVIMID). Our results show that anti-angiogenic activity spans both currently defined classes of thalidomide analogue and is not related to their previously described immunomodulatory properties. Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.

Copyright 2002 Cancer Research UK

Figures

Figure 1
Figure 1
Illustrates the effect of a thalidomide analogue, IMiD-1 (C,F) and suramin (B,E) in comparison to their relative controls (A,D) on microvessel outgrowths in the rat aorta assay (top row) and on tubule development in the human angiogenesis model (bottom row).
Figure 2
Figure 2
Inhibition of angiogenesis as demonstrated by the reduction of tubule development following co-culture for 11 days with SelCIDs (A) or with thalidomide or IMiDs (B) in the human angiogenesis model. The effect of suramin or VEGF on tubule development is also shown. . *=P<0.05 vs control (Dunnett's test).
Figure 3
Figure 3
Inhibition of angiogenesis as demonstrated by the reduction in the number of microvessels observed following co-culture with SelCIDs (A) or with IMiDs (B) in the rat aorta angiogenesis model. The effect of suramin on microvessel development is also shown. *=P<0.05 vs control (Dunnett's test).
Figure 4
Figure 4
The effect of Thd, IMiDs and SelCIDs on bFGF and VEGF-induced HUVEC proliferative responses. The data is representative of three independent experiments.
Figure 5
Figure 5
The effect of suramin and IMiD-1 on the migratory properties of EA.hy926 cells in an in vitro wound healing assay. Results are expressed as mean number of cells migrating per field. *=P<0.05 versus control (Dunnett's test).
Figure 6
Figure 6
The effect of IMiD-1 on the growth rate of CMT93 colorectal tumour in nude mice (A). Data is representative of at least two independent experiments. *=P<0.05 vs control (Dunnett's test). Histological examination revealed that treatment with IMiD-1 (bottom picture) increased necrosis within the tumour (B). Magnification ×400.

References

    1. BauerKSDixonSCFiggWD1998Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 5518271834
    1. BishopETBellGTBloorSBroomIJHendryNFKWheatlyDN2000An in vitro model of angiogenesis: Basic features Angiogenesis 34335344
    1. CarmelietPJainRK2000Angiogenesis in cancer and other diseases Nature 407249257
    1. CorralLGHaslettPAMullerGWChenRWongLMOcampoCJPattersonRTStirlingDIKaplanG1999Differential cytokine modulation and T cell activation by two distinct classes of Thd analogues that are potent inhibitors of TNF-α J Immunol 163380386
    1. D'AmatoJDLoughnanMSFlynnEFolkmanJ1994Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci 9140824085
    1. DanesiRDel BianchiSSoldaniPCampagniALa RoccaRVMyersCEPaparelliADel TaccaM1993Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane Br J Cancer 68932938
    1. Di SantoMEHeaslipRJ1993Identification and stabilization of large molecular weight PDE-IVs from U397 cells Biochem Biophys Res Comm 19711261128
    1. DonovanDBrownNJBishopETLewisCE2001Comparison of three in vitro human angiogenesis assays with capillaries formed in vivo Angiogenesis 42113121
    1. DrinkwaterSLSmithASawyerBMBurnardKG2002Effect of venous ulcer exudates on angiogenesis in vitro Br J Surg 896709713
    1. DudaDGSunamuraMLozonschiLKodamaTEgawaSMatsumotoGShimamuraHShibuyaKTakedaKMatsunoS2000Cancer Res 6011111116
    1. EdgellCJMcDonaldCCGrahamJB1983Permanent cell line expressing human factor VIII-related antigen established by hybridisation Proc Natl Acad Sci 8037343737
    1. FolkmanJ1971Tumour Angiogenesis: Therapeutic implications N Engl J Med 181182186
    1. FoxSBLeekRDWeekesMPWhitehouseRMGatterKCHarrisAL1995Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, chalkley count, and computer image analysis J Pathol 177275283
    1. FranksLHemmingsV1978A cell line from an induced carcinoma of a mouse rectum J Pathol 1243538
    1. GriffioenAWMolemaG2000Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 52237268
    1. HideshimaTChauhanDShimaYRajeNDaviesFETaiYTTreonSPLinBSchlossmanRLRichardsonPMullerGStirlingDIAndersonKC2000Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 9629432950
    1. HillPAMitchellRL1994Characterisation of phosphodiesterase activity from U937 cells FASEB J 8A217
    1. HolashJMaisonpierrePCComptonDBolandPAlexanderCRZagzagDYancopoulosGDWiegandSJ1999Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF Science 28419941998
    1. IguraKOhtaTKurodaYKajiK2001Resveratrol and quercetin inhibit angiogenesis in vitro Cancer Lett 1711116
    1. KenyonBMBrowneFd'AmatoRJ1997Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Exp Eye Res 64971978
    1. LiekensSBilsenFDe ClercqEPriegoEMCamarasaMJPerez-PerezMJBalzariniJ2001Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase FEBS 5101–28388
    1. MarriottJBClarkeIADredgeKMullerGStirlingDDalgleishAG2002Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells Clin Exp Immunol 1307584
    1. MarriottJBWestbyMCooksonSGuckianMGoodbournSMullerGShireMGStirlingDDalgleishAG1998CC-3052: A water soluble analogue of thalidomide and potent inhibitor of activation-induced TNF-α production J Immunol 16142364243
    1. MarriottJBMullerGStirlingDDalgleishAG2001Immunotherapeutic and anti-tumour potential of thalidomide analogues Expert Opin Biol Ther 118
    1. MoreiraALFriedlanderDPShifBKaplanGZagzagD1999Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro J Neuro-Oncol 43109114
    1. MullerGWShireMGWongLMCorralLGPattersonRTChenYStirlingDI1998Thalidomide analogues and PDE4 inhibition Bioorg Med Chem Lett 826692674
    1. NicosiaRFOttinettiA1990Growth of microvessels in serum-free matrix culture of rat aorta: a quantitative assay of angiogenesis in vitro Lab Invest 63115122
    1. OsugiTOshimaYFujioYFunamotoMYamashitaANegoroSKunisadaKIzumiMNakaokaYHirotaHOkabeMYamauchi-TakiharaKKawaseIKishimotoT2002Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart J Biol Chem 277866766681
    1. SinghalSMehtaJDesikanRAyersDRobersonPEddlemonPMunshiNAnaissieEWilsonCDhodapkarMZeldisJBarlogieB1999Antitumour activity of thalidomide in refractory multiple myeloma N Engl J Med 34115651571
    1. SmallEJMeyerMMarshallMEReynoLMMetersFJNataleRBLenehanPFChenLSlichenmyerWJEisenbergerM2000Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 1814401450
    1. SteinCALaRoccaRVThomasRMcAteeNMyersCE1989Suramin: an anticancer drug with a unique mechanism of action J Clin Oncol 7499508
    1. StevensonDPCollinsWPFarzanehFHataKMiyazakiK1998Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis Am J Pathol 15315731578
    1. TakanoSGatelySNevilleMEHerblinWFGrossJLEngelhardHPerriconeMEidsvoogKBremS1994Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator Cancer Res 5426542660
    1. TeraiYAbeMMiyamotoKKoikeMYamasakiMUedaMSatoY2001Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits angiogenesis via the bloackade of integrinaVb3 on vascular endothelial cells J Cell Physiol 188394402
    1. VoestEEKenyonBMO'ReillyMSTruittGd'AmatoRJFolkmanJ1998Inhibition of angiogenesis in vivo by interleukin 12 Int J Cancer 78361365
    1. WorkmanPTwentymanPBalkwillFBalmainAChaplinDDoubleJEmbletonJNewellDRaymondRStablesJStephensTWallaceJ1998United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia(Second Edition)Br J Cancer 77112

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe